US 9562237
Reduction of TGF beta signaling in myeloid cells in the treatment of cancer
granted A61KA61K2239/49A61K31/4025
Quick answer
US patent 9562237 (Reduction of TGF beta signaling in myeloid cells in the treatment of cancer) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Feb 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America, as represented by the Secretary, Department of Health and Human Services
- Grant date
- Tue Feb 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 6
- CPC classes
- A61K, A61K2239/49, A61K31/4025, A61K31/5377, A61K31/7088